Bristol-Myers Squibb Company (BMY) Thursday released the interim results from a Phase II open-label study of daclatasvir and GS-7977, a nucleotide NS5B polymerase inhibitor, used in treatment of patients with hepatitis C genotypes 1, 2 and 3.
The company stated that the analysis of a combination of the two oral, once-daily investigational compounds taken for 24 weeks, with or without ribavirin, achieved a rapid and sustained viral response.
The company further stated that 100% of patients with genotype 1, 2, or 3 HCV achieved viral load below the lower limit of quantification at Week 4 on treatment.
Mark Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center, Johns Hopkins University School of Medicine, said:. "The interim results of this study indicate that combining the potent antiviral activity of daclatasvir with a nucleotide analogue polymerase inhibitor has the potential to address this goal for the treatment of HCV genotypes 1, 2 and 3, and warrants further study to more fully evaluate this combination."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org